Sardona Therapeutics is developing new small molecule drugs targeting RNA-binding proteins in the spliceosome to provide patients with therapy resistant cancers new treatment options.↓
RNA dysregulation is a major driver of cancer therapeutic resistance, leading to metastatic disease. Aberrant function of RNA binding proteins in the spliceosome leads to RNA dysregulation and loss of normal protein production.
Sardona built a novel platform to identify new precision oncology small molecule drugs that target RNA-binding proteins in the spliceosome and links them to clinically validated genetic alterations.
Sardona’s unique approach has resulted in compounds that inhibit previously undruggable oncogenic drivers. Because of this, we believe that we can provide patients with therapy resistant cancers new and more durable treatment options.
Our team built the leading drug discovery platform to target RNA binding proteins (RBPs). The platform’s foundation is Sardona’s proprietary RBP Topography Map that links different RBPs in the spliceosome to specific therapy resistant cancers. We leverage internally developed screening assays, bioinformatics capabilities and focused small molecule compound libraries to generate best-in-class drug candidates that target individual RBPs. Our unique approach has resulted in new lead compounds for previously undruggable oncogenic signaling pathways that drive therapy resistance.
At Sardona Therapeutics, we are blazing a trail for a new way to target clinically established oncogenic pathways driving therapy resistance. With a precision oncology approach, we are advancing our initial programs with the potential to address high unmet needs in various types of genetically defined, metastatic cancer, including breast cancer, non-small cell lung cancer, and colorectal cancer.
By 2030, more than 30 million people in the U.S. will have therapy resistant cancers. We need to act boldly now and explore new approaches. That’s why Sardona Therapeutics is pushing the limits to advance a new class of drugs targeting cancer’s core mechanism and going further to expand the therapeutic options to fight aggressive cancers.Join Us